Immucor faces FTC (Federal Trade Commission) probe over acquisitions
This article was originally published in Clinica
Executive Summary
Blood screening specialist Immucor has come under the scrutiny of the US Federal Trade Commission (FTC) in a non-public investigation over a possible breach of federal antitrust laws. The FTC sent Immucor a letter, received on October 12, requesting certain documents and information connected to three acquisitions made from 1996 to 1999. These were a $4.5m purchase of monoclonal antibody-based reagent maker Dominion Biologicals (Halifax, Nova Scotia); a $25m deal for blood serology reagents specialist Gamma Biologicals (Houston, Texas); and the acquisition of the immunohaematology business belonging to Ventura, California-based Biopool International for approximately $8.5m in cash and mixed notes.